series-b
Stage
1
Investors
About
Scynexis is a clinical-stage biopharmaceutical company developing innovative therapies for severe rare diseases, focusing on treatments for autosomal dominant polycystic kidney disease (ADPKD) via AMPK activators and antifungal agents addressing antimicrobial resistance.
Explore Scynexis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.